scholarly journals The Kiss of Death: A Severe Allergic Reaction to a Shellfish Induced by a Good-Night Kiss

2003 ◽  
Vol 78 (2) ◽  
pp. 221-222 ◽  
Author(s):  
David P. Steensma
Keyword(s):  
Allergic Reaction ◽  
Severe Allergic Reaction ◽  
Good Night

scholarly journals WITHDRAWN: Severe allergic reaction following Histrelin implant (Supprelin LA)

2020 ◽  
pp. 101398
Author(s):  
Sara Donnelly ◽  
Dana Shuriff ◽  
Steven Stylianos ◽  
Jeffrey Zitsma
Keyword(s):  
Allergic Reaction ◽  
Severe Allergic Reaction

scholarly journals Severe Allergic Reaction to Dermabond

2009 ◽  
Vol 29 (4) ◽  
pp. 314-316 ◽  
Author(s):  
Arthur W. Perry ◽  
Michael Sosin
Keyword(s):  
Allergic Reaction ◽  
Severe Allergic Reaction

A case of severe allergic reaction to cooked potato

2011 ◽  
Vol 100 (11) ◽  
pp. e236-e238 ◽  
Author(s):  
G Monti ◽  
S Viola ◽  
V Tarasco ◽  
MM Lupica ◽  
V Cosentino ◽  
...  
Keyword(s):  
Allergic Reaction ◽  
Severe Allergic Reaction

scholarly journals Severe allergic reaction following histrelin implant (Supprelin LA)

2015 ◽  
Vol 3 (11) ◽  
pp. 523-525 ◽  
Author(s):  
Sara Donnelly ◽  
Dana Shuriff ◽  
Steven Stylianos ◽  
Jeffrey Zitsman
Keyword(s):  
Allergic Reaction ◽  
Severe Allergic Reaction

scholarly journals Report of a rare case of severe allergic reaction due to nasal myiasis and a brief review of the literature in Turkey

2019 ◽  
Vol 7 ◽  
pp. 2050313X1984339 ◽  
Author(s):  
Ali Kemal Erenler ◽  
Ahu Pınar Turan ◽  
Özlem Oymak Ay ◽  
Ayşegül Taylan Özkan
Keyword(s):  
Emergency Department ◽  
Allergic Reaction ◽  
Rare Case ◽  
Current Status ◽  
Severe Allergic Reaction ◽  
Shortness Of Breath ◽  
Definite Diagnosis ◽  
Review Of The Literature ◽  
Living Tissues ◽  
Nasal Myiasis

Myiasis is defined as infestation of a mammal by fly larvae. It may occur on either living tissues (primary myiasis) or dead tissues (secondary myiasis). In this report, we present a patient with myiasis with an extremely rare clinical manifestation and severe allergic reaction, and we review the literature in order to reveal the current status. A 20-year-old female patient was admitted to our emergency department due to rush on face, cough and shortness of breath. The maggot came out of her nose was identified as Oestrus ovis. With a diagnosis of severe allergic reaction due to myiasis, she was treated diphenhidramine, prednisone and inhale albuterol in the emergency department. After treatment and further investigation, she was discharged with full recovery. Myiasis is a rare cause for severe allergic reaction in patients with definite diagnosis. Immediate diagnosis and treatment are milestones in preventing bad outcomes.

Severe allergic reaction to gluten hydrolysate without reaction to wheat

2011 ◽  
Vol 106 (4) ◽  
pp. 343-344 ◽  
Author(s):  
Anna S. Pelkonen ◽  
Soili Mäkinen-Kiljunen ◽  
Sirpa Hilvo ◽  
Mirjami Siltanen ◽  
Mika J. Mäkelä
Keyword(s):  
Allergic Reaction ◽  
Severe Allergic Reaction

scholarly journals Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA

2021 ◽  
Author(s):  
Ludger Klimek ◽  
Natalija Novak ◽  
Eckard Hamelmann ◽  
Thomas Werfel ◽  
Martin Wagenmann ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Allergic Reaction ◽  
Repeated Administration ◽  
Phase Iii ◽  
Foreign Protein ◽  
Severe Allergic Reaction ◽  
Allergic Reactions ◽  
Pivotal Phase ◽  
Other Substances ◽  
Life Threatening

SummaryTwo employees of the National Health Service (NHS) in England developed severe allergic reactions following administration of BNT162b2 vaccine against COVID-19 (coronavirus disease 2019). The British SmPC for the BNT162b2 vaccine already includes reference to a contraindication for use in individuals who have had an allergic reaction to the vaccine or any of its components. As a precautionary measure, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued interim guidance to the NHS not to vaccinate in principle in “patients with severe allergies”. Allergic reactions to vaccines are very rare, but vaccine components are known to cause allergic reactions. BNT162b2 is a vaccine based on an mRNA embedded in lipid nanoparticles and blended with other substances to enable its transport into the cells. In the pivotal phase III clinical trial, the BNT162b2 vaccine was generally well tolerated, but this large clinical trial, used to support vaccine approval by the MHRA and US Food and Drug Administration, excluded individuals with a “history of a severe adverse reaction related to the vaccine and/or a severe allergic reaction (e.g., anaphylaxis) to a component of the study medication”. Vaccines are recognized as one of the most effective public health interventions. This repeated administration of a foreign protein (antigen) necessitates a careful allergological history before each application and diagnostic clarification and a risk–benefit assessment before each injection. Severe allergic reactions to vaccines are rare but can be life-threatening, and it is prudent to raise awareness of this hazard among vaccination teams and to take adequate precautions while more experience is gained with this new vaccine.

scholarly journals POS0600 IMMUNOGENICITY OF RITUXIMAB BIOSIMILAR GP2013: A RARE EVENT, BUT NOT WITHOUT CONSEQUENCES ...

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 534-535
Author(s):  
J. Avouac ◽  
R. Cougnaud Murail ◽  
C. Goulvestre ◽  
S. Dumas ◽  
A. Moltó ◽  
...  
Keyword(s):  
Allergic Reaction ◽  
Disease Duration ◽  
Controlled Trial ◽  
Rare Event ◽  
Treatment Discontinuation ◽  
Severe Allergic Reaction ◽  
High Antibody ◽  
Entire Treatment Period ◽  
Clinical Consequences ◽  
Antibody Levels

Background:The bioequivalence between rituximab (RTX) originator and its biosimilar GP2013 has been demonstrated in rheumatoid arthritis (RA) (1). A recent randomized controlled trial suggested in a selected population a very low immunogenicity of GP2013 in RA (<1%) (2).Objectives:To study in daily practice the risk of immunogenicity of patients treated with GP2013 for their chronic inflammatory rheumatic disorder.Methods:Prospective routine care study carried out between September 2018 and August 2020 in the Rheumatology department of Cochin Hospital. We consecutively included patients treated with the biosimilar RTX GP2013, systematically used in the department since March 2018. Samples were taken before each infusion in order to detect anti-RTX antibodies (Ab) and RTX residual concentrations by ELISA (Lisa Tracker Duo Rituximab, LTR005, Theradiag).Results:We included 159 consecutive patients treated with GP2013 (124 women, 78%) with a mean age of 59±13 years and a mean disease duration of 18±11 years. Among these 159 patients, 108 (68%) had RA and 51 had another disease (16 systemic sclerosis (SSc), 15 mixed connective tissue disease (MCTD), 5 systemic lupus (SLE), 5 inflammatory myopathies (MI), 5 undifferentiated polyarthritis, 2 juvenile idiopathic arthritis (JIA) and 3 primary Sjögren’s syndromes). 137 patients (86%) were receiving associated disease-modifying therapy (DMARD), mainly methotrexate (111/137 patients, 81%). 120 patients (75%) were in maintenance therapy with originator RTX (cumulative dose of RTX: 3.5±6g) before the switch to GP2013 in March 2018. Originator RTX was not re-established during the entire treatment period. The other 39 patients (25%) treated with GP2013 were naïve of originator RTX.The analysis of the first sample, performed before the second GP2013 infusion, identified 8 patients (5 RA, 1 SLE, 1 MCTD and 1 SSc) with positive anti-RTX antibodies (prevalence 5%), with rates varying between 6 and >100ng/mL and undetectable residual RTX concentrations. Among these 8 patients, 6 had previously received originator RTX and 2 were RTX-naïve patients. There was a trend for higher body mass index in patients with positive anti-RTX antibodies (28±7 vs. 25±6 kg/m2, p=0.12), and no association was observed between anti-RTX immunization and age, disease duration, combination with conventional DMARD, mean interval between infusions or cumulative RTX dose.Among the 8 immunized patients, two groups could be isolated: i) a group of 5 patients (3 RA, 1 SLE, 1 SSc) with low antibody levels (6-22 ng/mL) and no significant clinical consequences (absence of treatment discontinuation and loss of efficacy after 13±4 months of follow-up, only one minor allergic reaction) and ii) a group of 3 patients (2 RA, 1 MCTD) with a high antibody levels (≥100ng/mL) and meaningful clinical consequences: one severe allergic reaction during the second GP2013 infusion leading to treatment discontinuation, and a loss of efficacy with incomplete B depletion in 2 patients leading to RTX dose escalation from 500 mg to 1 g. Among the 151 patients not immunized at the time of the first sample, no severe allergic reaction and 6 minor allergic reactions were noted under GP2013.Conclusion:The immunogenicity of patients treated with RTX is a rare event with possible clinical and biological consequences, especially in patients with high antibody levels.References:[1]Smolen et al, Ann Rheum Dis 2017[2]Tony et al, Arthritis Care Res 2019Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document